Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00788541 · ClinicalTrials.gov registry record · Phase 2
A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension
A Phase 2 study, sponsored by Alcon Research.
- Terminated
- Registry status
- Phase 2
- Development phase
- 197
- Enrollment target
NCT00788541: Clinical Trial Phase 2 study, sponsored by Alcon Research.
NCT00788541 is a Phase 2 study that was terminated before completion, run by Alcon Research. The registered enrollment target is 197 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (48% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00788541, a Phase 2 study, was terminated before completion, sponsored by Alcon Research.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 197 participants
- Enrollment target
Study Summary
The purpose of this study was to assess the effects of total volume and total dose on the safety and intraocular pressure-lowering efficacy of Anecortave Acetate Suspension (3 mg and 48 mg) in 0.5 mL and 0.8 mL volumes when administered by anterior juxtascleral depot (AJD) for the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Interventions
- OTHER Anecortave Acetate Vehicle
- DRUG Anecortave Acetate Sterile Suspension, 6 mg/mL
- DRUG Anecortave Acetate Sterile Suspension, 3.75 mg/mL
- DRUG Anecortave Acetate Sterile Suspension, 96 mg/mL
- DRUG Anecortave Acetate Sterile Suspension, 60 mg/ML
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2008-12 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
Why NCT00788541 stopped before completion
NCT00788541 is an interventional study that assigns participants to a tested intervention. The registered 197 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (48% higher).
The record links to 0 conditions, and to 5 interventions - of which Anecortave Acetate Vehicle is the first listed.
NCT00788541 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00788541 about?
NCT00788541 is a clinical study titled "A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension". The purpose of this study was to assess the effects of total volume and total dose on the safety and intraocular pressure-lowering efficacy of Anecortave Acetate Suspension (3 mg and 48 mg) in 0.5 mL and 0.8 mL volumes when administered by anterior juxtascleral depot (AJD) for the treatment of eleva...
What is the current status of trial NCT00788541?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 197 participants. The study started on 2008-12. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00788541?
The interventions under investigation include: Anecortave Acetate Vehicle (OTHER), Anecortave Acetate Sterile Suspension, 6 mg/mL (DRUG), Anecortave Acetate Sterile Suspension, 3.75 mg/mL (DRUG), Anecortave Acetate Sterile Suspension, 96 mg/mL (DRUG), Anecortave Acetate Sterile Suspension, 60 mg/ML (DRUG).
Who is sponsoring clinical trial NCT00788541?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00788541's enrollment target sits among peer trials
197 349th of 2000 higher than 1,652 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04219254 · 197 participants · Phase 1
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
- NCT06173778 · 197 participants · Phase 2
Semaglutide for Post-Smoking Cessation Weight Management
- NCT05203328 · 198 participants · NA
Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy
- NCT05426967 · 198 participants · NA
rTMS for Military TBI-related Depression
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia